PT  - JOURNAL ARTICLE
AU  - Kuznar, Wayne
ED  - Page, Richard L.
TI  - Promising Agent Identified as Specific Antidote to Factor Xa Inhibition
DP  - 2014 Sep 01
TA  - MD Conference Express
PG  - 17--17
VI  - 14
IP  - 21
4099  - http://mdc.sagepub.com/content/14/21/17.short
4100  - http://mdc.sagepub.com/content/14/21/17.full
AB  - Antidotes to Factor Xa inhibitors are under development and should enhance the safety of the new oral anticoagulant (NOAC) agents. Reversal of a NOAC is necessary in certain circumstances, such as a spontaneous or provoked hemorrhage (rate of 10% to 20% in Phase 3 trials), an emergency or invasive procedure that requires the rapid reversal of anticoagulation, or serious bleeding in a critical organ.